4-Propyl-isoquinoline | 114273-43-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 4-Propyl-isoquinoline
• 英文别名: 4-Propylisoquinoline
• CAS: 114273-43-7
• 化学式: C₁₂H₁₃N
• 分子量: 171.242
• InChiKey: AMEFTOJIMPAFFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  丙醛 、 sodium;triethyl(1H-isoquinolin-2-yl)boranuide 在 sodium hydroxide 、 双氧水 作用下， 生成 4-Propyl-isoquinoline
  参考文献：
  名称：

  A new synthesis of 4-substituted isoquinolines

  摘要：

  DOI：

  10.1021/jo00246a056

文献信息

• PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE
  申请人：Okamoto Kuniaki

  公开号：US20120130107A1

  公开（公告）日：2012-05-24

  Object To provide a method for producing a bis-quaternary ammonium salt efficiently and a novel synthetic intermediate thereof. Solution The present invention relates to a method for producing a bis-quaternary ammonium salt represented by a general formula [3] which comprises reacting a disulfonic acid ester represented by a general formula [1] (in the formula, definitions of two R 1 's and T are as described in claim 1 ) with a tertiary amine represented by a general formula [2] (in the formula, definitions of R 3 to R 5 are as described in claim 1 ), and a disulfonic acid ester represented by a general formula [1′] (in the formula, two R 16 's represent independently a halogen atom or a C1-C3 fluoroalkyl group, and two m's represent independently an integer of 1 to 5).

  提供一种高效生产双季铵盐和其新型合成中间体的方法。本发明涉及一种生产由通用式[3]表示的双季铵盐的方法，包括将由通用式[1]表示的二磺酸酯（在该式中，两个R1和T的定义如权利要求1中所述）与由通用式[2]表示的三级胺（在该式中，R3到R5的定义如权利要求1中所述）以及由通用式[1']表示的二磺酸酯（在该式中，两个R16独立表示卤原子或C1-C3氟烷基，两个m独立表示1至5的整数）反应。
• Novel disulfonic acid ester as an additive for an electrolyte for a lithium secondary battery
  申请人：Wako Pure Chemical Industries, Ltd.

  公开号：EP2821395A2

  公开（公告）日：2015-01-07

  Object To provide a method for producing a bis-quaternary ammonium salt efficiently and a novel synthetic intermediate thereof. Solution The present invention relates to a method for producing a bis-quaternary ammonium salt represented by a general formula [3] which comprises reacting a disulfonic acid ester represented by a general formula [1] (in the formula, definitions of two R1's and T are as described in Claim 1) with a tertiary amine represented by a general formula [2] (in the formula, definitions of R3 to R5 are as described in Claim 1), and a novel disulfonic acid ester represented by a general formula [1'] (in the formula, two R16's represent independently a halogen atom or a C1-C3 fluoroalkyl group, and two m's represent independently an integer of 1 to 5) as an additive for an electrolyte for a lithium secondary battery.

  目的 提供一种高效生产双季铵盐的方法及其新型合成中间体。 本发明涉及一种生产通式[3]代表的双季铵盐的方法，该方法包括将通式[1]代表的二磺酸酯（式中，两个 R1 和 T 的定义如权利要求 1 所述）与通式[2]代表的叔胺（式中、R3至R5的定义如权利要求1所述），以及通式[1']代表的新型二磺酸酯（式中，两个R16独立地代表卤素原子或C1-C3氟烷基，两个m独立地代表1至5的整数），作为锂二次电池电解液的添加剂。
• Inhibitors of c-Jun-N-terminal kinase (JNK)
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10981903B2

  公开（公告）日：2021-04-20

  The present invention provides novel compounds according to Formula (I): where Ring A, Ring B, X, L1, L2, RA, RC, RD, RE, m, n, and p are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of human diseases associated with kinase activity, for example, proliferative diseases, neurodegenerative diseases, metabolic disorders, inflammatory diseases, and cardiovascular diseases.

  本发明提供了符合式（I）的新型化合物： 其中环 A、环 B、X、L1、L2、RA、RC、RD、RE、m、n 和 p 如本文所定义。本发明的化合物可用于预防和治疗多种与激酶活性相关的人类疾病，例如增殖性疾病、神经退行性疾病、代谢紊乱、炎症性疾病和心血管疾病。
• MINTER, DAVID E.;RE, MICHAEL A., J. ORG. CHEM., 53,(1988) N 11, 2653-2655
  作者：MINTER, DAVID E.、RE, MICHAEL A.

  DOI：——

  日期：——
• INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK)
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20190248778A1

  公开（公告）日：2019-08-15

  The present invention provides novel compounds according to Formula (I): where Ring A, Ring B, X, L 1 , L 2 , R A , R C , R D , R E , m, n, and p are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of human diseases associated with kinase activity, for example, proliferative diseases, neurodegenerative diseases, metabolic disorders, inflammatory diseases, and cardiovascular diseases.